Navigation Links
caprotec bioanalytics Announces Issuance In Europe of All Core Patents of Its CCMS Technology
Date:2/28/2011

BERLIN, and BURLINGTON, Mass., Feb. 28, 2011 /PRNewswire/ -- caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry (CCMS) technology.  

CCMS offers a novel and direct way to investigate small molecule - protein interactions resulting in a significant functional reduction of proteome complexity. The core of the CCMS technology consists of tri-functional small molecules called Capture Compounds™.  These Capture Compounds enable the direct isolation and identification of selected proteins, including membrane proteins, out of any complex biological sample.

An important application of the CCMS technology is to profile small molecule drug - protein interactions in the human proteome to discover or confirm relevant protein drug targets, the mode of drug action, and off-target proteins potentially causing adverse side effects in humans.

The newly granted European Patent No. EP 1583972 titled "Methods for Identifying Drug Non-targets" covers the use of CCMS technology for lead optimization and risk assessment of candidate drugs to make a go or no-go decision to enter the clinical trial phase.  The European Patent No.  EP  1485707 titled "Compounds and Methods for Analyzing the Proteome" covers Capture Compounds and methods to discover protein biomarkers for diagnostic applications. European Patent No. EP 1502102 titled "Compounds and Methods for Analyzing the Proteome" covers an array-based application of CCMS technology.  Equivalent patents have been issued in many major countries.

"We are pleased about the grant of the last of our three core CCMS patents in Europe, which protect our proprietary technology and endorse the uniqueness of this powerful proteome analysis technology," states Prof. Dr. Hubert Koester, Founder and Chief Executive Officer of caprotec bioanalytics GmbH.  

These new patents are additions to an already significant patent estate of the company in the fields of biopolymer syntheses, functional genomics using ribozymes, and mass spectrometry-based multiplex protein expression analysis.

The company is involved in collaborations applying CCMS technology with pharmaceutical companies to evaluate and optimize drug candidates (see press release from June 28, 2010; "caprotec bioanalytics Announces  the Successful Completion of a Collaborative Research Project With Hoffmann-LaRoche").

About caprotec bioanalytics GmbH

caprotec bioanalytics GmbH was founded by Prof. Dr. Hubert Koester in 2006 and is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of proteomics, drug development and development of protein biomarkers.

The Company holds a vast portfolio of 41 international patents of which 21 are already granted. The technology has been validated through proof-of-principle experiments in all three fields of application and has been described in experimental detail in several peer-reviewed publications.  caprotec is supported by an international scientific advisory board including a Nobel Laureate.

www.caprotec.com


'/>"/>
SOURCE caprotec bioanalytics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
2. caprotec bioanalytics Announces Commercial Launch of Three New caproKits™ for Applications in Functional Proteomics and Drug Development
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
Breaking Medicine News(10 mins):